The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-Kras G12D/+ transgenic mouse model

Cancer Prevention Research

Volumn 3, Issue 11, 2010, Pages 1417-1426

  Mohammed, Altaf ^a   Janakiram, Naveena B ^a   Li, Qian ^a   Madka, Venkateshwar ^a   Ely, Misty ^a   Lightfoot, Stan ^b   Crawford, Howard ^c   Steele, Vernon E ^d   Rao, Chinthalapally V ^a  

^a Hematology Oncology Section   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CAVEOLIN; CYCLIN D1; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DIET; DISEASE MARKER; EXPERIMENTAL MODEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TRANSGENIC ANIMAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78649278460     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0038     Document Type: Article

References (52)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta (GA); 2007.
2. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs 2006;15:1395-410. (Pubitemid 44615288)
3. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
4. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 2006;66:95-106.
5. Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 2005;70:65-72.
6. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-50.
7. Kawaguchi B, Cooper M, Gannon M, et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet 2002;32:128-34.
8. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-8. (Pubitemid 34008190)
9. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006;12:5277-87.
10. Pryczynicz A, Guzin K, Kemona A, Ewska JC. Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res 2004;28:1399-404.
11. Durkin AJ, Bloomston PM, Rosemurgy AS, et al. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg 2003;186:431-6.
12. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α. J Clin Invest 1992;90:1352-60.
13. Takemura S, Yashiro M, Sunami T, Tendo M, Hirakawa K. Novel models for human scirrhous gastric carcinoma in vivo. Cancer Sci 2004;95:893-900.
14. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski L. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005;24:1809-19.
15. Held-Feindt J, Lutjohann B, Ungefroren H, Mehdorn HM, Mentlein R. Interaction of transforming growth factor-β (TGF-β) an epidermal growth factor (EGF) in human glioma cells. J Neurooncol 2003;63:117-27. (Pubitemid 36705681)
16. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
17. Bruns CJ, Solorzano CC, Habrison MT, et al. Blockade of epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
18. Brehmer D, Greff Z, Godl K, et al. Cellular targets of gefitinib. Cancer Res 2005;65:379-82.
19. Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7.
20. Wirth LJ, Haddad RI, Wieczorek TJ, et al. Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2004;23:496.
21. Albain K, Elledge R, Gradishar WJ, et al. Open-label, phase II, multi-center trial of ZD1839 ("Iressa") in patients with advanced breast cancer. Breast Cancer Res Treat 2002;76:33.
22. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib (ZD1839) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2003;22:7.
23. Gee JMW, Harper ME, Hutcheson IR, et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003;144:5105-17.
24. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004;90:236-44.
25. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
26. McKillop D, Raab G, Eidtmann H, et al. Intratumoral and plasma concentrations of gefitinib ("Iressa") in breast cancer patients: preliminary results from a presurgical investigatory study (BCIRG 103). J Clin Oncol 2004;22:581.
27. Fisher GA, Kuo T, Cho CD, et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004;23:249.
28. Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability, and pharmacokinetics of gefitinib ("Iressa," ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003;22:258.
29. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (Iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-4.
30. Feng FY, Lopez CA, Normolle DP, et al. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res 2007;13:2512-8.
31. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225). superiority over single-agent receptor targeting. Clin Cancer Res 2004;10:6487-501.
32. Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 2006;24:656-62.
33. Maurel J, Martin-Richard M, Conill C, et al. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2006;66:1391-8.
34. Smit VT, Boot AI, Smits AM, et al. KRAS codon mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1998;16:7773-82.
35. Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-49.
36. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000;156:1821-5.
37. Wagner M, Greten FR, Weber CK, et al. Genes Dev 2001;15:286-93.
38. Wagner M, Weber CK, Bressau F, et al. Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells. Gastroenterology 2002;122:1898-12.
39. Steven DL. Mouse models of pancreatic cancer: the fur is finally flying! Cancer Cell 2004;5:7-11.
40. Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 2007;25:4506-7.
41. Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Res Critical Care Med 2006;174:550-6. (Pubitemid 44330548)
42. Hattori K, Iida K, Joraku A, Tsukamoto S, Akaza H, Oyasu R. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int 2006;97:640-3.
43. Ohashi K, Takigawa N, Osawa M, et al. Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. Cancer Res 2009;69:7088-95.
44. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005;41:307-14.
45. Funahashi H, Satake M, Dawson D, et al. Delayed progression of pancreatic intraepithelial neoplasia in a conditional KrasG12D mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 2007;67:7068-71.
46. Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol 2007;171:263-73. (Pubitemid 47339243)
47. Tanase CP, Dima S, Mihai M, et al. Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. J Mol Hist 2009;40:23-9.
48. Witkiewicz AK, Nguyen KH, Dasgupta A, et al. Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle 2008;7:3021-5.
49. Muslimov GF. Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma. Bull Exp Biol Med 2008;145:4.
50. Suzuoki M, Miyamoto M, Kato K, et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002;87:1140-4.
51. 2-M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia 2000;2:261-72.
52. Matsubayashi H, Watanabe H, Nishikura K, Ajioka Y, Kijima H, Saito T. Determination of pancreatic ductal carcinoma histogenesis by analysis of mucous quality and K-ras mutation. Cancer 1998;82:651-60.